Updated:
Founder H Fund
Founder H Fund Co., Ltd. (方正和生投资有限责任公司) is a wholly-owned private equity fund subsidiary of Founder Securities Co., Ltd. It focuses on scientific and...
Founder H Fund
Founder H Fund Co., Ltd. (方正和生投资有限责任公司) is a wholly-owned private equity fund subsidiary of Founder Securities Co., Ltd. It focuses on scientific and technological innovation and commercialization in areas aligned with national strategy, with both early-stage and growth-stage funds. Assets under management are nearly RMB 20 billion, with investments in more than 170 companies.
General information
Firm type
Private Equity
Year founded
2010
Location
Region
Asia
Country
China
City
Beijing
Corporate office
Beijing, China
Principals
姜志军（董事长、法定代表人）
李岩（董事）
张军（董事）
韩长风（总裁）
李秀娟（联席总裁）
季铭（合规负责人）
赵强（财务负责人）
Sector focus
Frequently asked questions
Who runs investment decisions at Founder H Fund?
The firm does not publish a named investment committee or principal roster on its corporate website. As a wholly owned subsidiary of Founder Securities, key investment and operational oversight lines run to the parent's PE division, which is regulated by the China Securities Regulatory Commission.
How is Founder H Fund's healthcare capital split between its vehicles?
The healthcare strategy operates through two disclosed onshore funds: a $100 million growth-stage vehicle targeting medical services, devices, IT, and pharmaceuticals, and a RMB 300 million early-stage fund focused on precision medicine, medical devices, drug R&D, and healthcare services (per the firm).
Does Founder H Fund operate any offshore or USD-denominated strategies?
Except for the $100 million healthcare growth fund, which is USD-denominated but remains onshore in structure, the firm's three other disclosed vehicles — RMB 300 million, RMB 1 billion, and RMB 5 billion — are all RMB-denominated. No offshore or Cayman-domiciled funds are listed.
What investment stages does Founder H Fund typically target?
The firm's four main vehicles span seed to pre-IPO. The early-stage RMB 300 million and RMB 1 billion funds target seed and startup rounds, while the RMB 5 billion tech growth fund and $100 million healthcare growth fund pursue expansion, late-stage, and pre-IPO deals. PIPE investments and fund-of-funds commitments are also within the disclosed mandate (per the firm).
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on private equity firms?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: